Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Novo Nordisk

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              DENMARK Denmark

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Novo Nordisk Successfully Completes AM833 Phase 2 Trial and Phase 1 Combination Trial with AM833 and Semaglutide in Obesity

              Contact the Supplier

              Lead Product(s): Fleroxacin

              Therapeutic Area: Nutrition and Weight Loss Product Name: AM833

              Highest Development Status: Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 18, 2020

              Details:

              The 26-week blinded phase 2 monotherapy trial with AM833 investigated safety, tolerability and efficacy for weight management in 706 people with obesity or overweight with at least one weight-related comorbidity.

              Saniona

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              DENMARK Denmark

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Saniona Reports Positive Topline Results from Phase 2 Trial of Tesomet in Hypothalamic Obesity

              Contact the Supplier

              Lead Product(s): Tesofensine

              Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 22, 2020

              Details:

              Study results showed that Tesomet was safe and well tolerated. Robust efficacy data reported statistically significant improvements in body weight, waist circumference, and glycemic control.

              Saniona

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              DENMARK Denmark

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Saniona completes its six months double blind Phase 2a trial of Tesomet in hypothalamic obesity

              Contact the Supplier

              Lead Product(s): Tesofensine

              Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 18, 2020

              Details:

              A total of 18 patients, of the original 21 who started the trial, have now continued into the open-label extension part of the study.

              Lipidio Pharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Lipidio Pharmaceuticals Launches with First Close of Series A Financing

              Contact the Supplier

              Lead Product(s): GDD3898

              Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Maxim Merchant Capital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Series A Financing March 03, 2020

              Details:

              The financing will support the development of its lead therapeutic candidate GDD3898.

              PharmaCompass__DigitalAd